Connect with us

Technology

Brainomix Completes £14M ($18M) Series C Round to Advance Its Transformative AI Imaging Technology in Healthcare

Published

on

University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatmentsFunding will also support clinical uptake of its breakthrough solution in lung fibrosis

OXFORD, England and CHICAGO, March 20, 2025 /PRNewswire/ — Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a £14M ($18M) Series C investment round. The round is co-led by prominent healthtech investors that include existing investors, Parkwalk Advisors, the UK’s largest growth EIS fund manager, and the Boehringer Ingelheim Venture Fund (BIVF), along with new investor Hostplus via the IP Group Hostplus Innovation Fund. Hostplus is a leading Australian industry superannuation (pension) fund with over AUD$120 billion in funds under management. The round was supported by LifeSci Capital.

A spinout from the University of Oxford, Brainomix now operates in more than 20 countries globally, including the US. It has pioneered the development of an AI platform, Brainomix 360 Stroke, that automates validated imaging biomarkers to improve both diagnosis and treatment decisions. Brainomix is the established European market leader, with a NICE-endorsed technology that has been deployed to more than 300 hospitals, having benefitted more than 1.5M patients.

The company has demonstrated a unique ability to impact treatment rates, with results showing that Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, a life-changing stroke treatment reducing disability.

This new investment will enable Brainomix to accelerate its commercial expansion into the US, where the company has recently secured ten FDA clearances. Fresh funding will also support Brainomix to advance its portfolio of AI-powered technology in new areas, facilitating faster diagnosis and increasing access to life-saving treatments. Having grown to a company of more than 75 staff, Brainomix plans to expand both its Oxford-based operations and global commercial team.

Brainomix has applied its AI expertise to lung fibrosis, with the development and FDA clearance of its Brainomix 360 e-Lung technology to accurately predict the progression of the disease. The company has an ongoing partnership with Boehringer Ingelheim, the global leader in lung fibrosis treatments, to evaluate the real-world impact of e-Lung to improve the identification and access to treatment for people with progressive lung fibrosis.

Dr Michalis Papadakis, CEO and Co-Founder at Brainomix, said: “We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognize the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies.”

John Pearson, Chief Investment Officer at Parkwalk, said: “The potential for AI-powered platforms in healthcare to revolutionise diagnosis and treatment decisions is clear. Brainomix has successfully demonstrated its platform imaging software is able to deliver both significant societal impact and strong growth for investors. Parkwalk is excited to continue supporting a company that is creating comprehensive solutions to critical needs and implementing them at scale.”

Dr Oliver Reuss, Investment Manager of the Boehringer Ingelheim Venture Fund (BIVF) and Director of the Brainomix Board, said:  “Brainomix has demonstrated an unparalleled track record of successfully delivering AI solutions into stroke clinical practice, and they are now doing it again in lung fibrosis. As a strategic investor with a shared vision to enhance care for lung disease, we believe Brainomix has the potential to improve the identification and access to treatment for people with lung fibrosis.”

Please watch our video here Brainomix Series C Funding – Dr Michalis Papadakis on Vimeo

Notes to Editors

About Brainomix
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 20 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on TwitterLinkedIn and Facebook.

Contacts
Jeff Wyrtzen, Chief Marketing & Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730

Media Enquiries 
Charles Consultants
Christopher Gardner
chris@cgcomms.onmicrosoft.com
M +44 (0)7956 031077

About Parkwalk 
Parkwalk is the largest growth EIS fund manager, backing world-changing technologies emerging from the UK’s leading universities and research institutions. With £500m of assets under management, it has invested in over 180 companies across its award-winning Parkwalk Opportunities and Knowledge Intensive EIS Funds, as well as the enterprise and innovation funds Parkwalk manages for the Universities of Cambridge, Oxford, Bristol and Imperial College. 

For further information visit: parkwalkadvisors.com  

Media Enquiries 
Portland
Pauline Guénot
Pauline.guenot@portland-communications.com
+44 (0)7841 196889

About IP Group Hostplus Innovation Fund
IP Group is the leading investor in university originated deep-tech companies in Australia and the UK. The Group pioneered a unique approach to developing intellectual property into valuable deep-tech companies.  

In Australia and New Zealand, IP Group manages the $435m IP Group Hostplus Innovation Fund.  IP Group works in close partnership with major universities to identify ground-breaking technologies which have the most promising commercial potential. IP Group, which is listed on the Main Market of the London Stock Exchange under the symbol IPO, has a strong track record of success and its portfolio comprises holdings in early stage to mature businesses across life sciences and technology. https://www.ipgroupanz.com/

Media contact:
Craig Regan, Primary Communication on +61 (0) 408 448 527 or craig@primarycommsgroup.com.au

About Boehringer Ingelheim Venture Fund GmbH
The Boehringer Ingelheim Venture Fund (BIVF), established in 2010, is dedicated to investing in groundbreaking biotechnology companies that are at the forefront of therapeutic and digital innovations, aiming to advance biomedical research. With a commitment to revolutionizing the standard of care, the BIVF fosters long-term partnerships with scientists and entrepreneurs. The BIVF’s focus is on nurturing disease-modifying therapeutic concepts and facilitating their clinical application. The BIVF prioritizes the translation of first-in-class concepts that address significant medical needs in fields such as oncology, immunology, regenerative medicine, neurodegeneration, infectious diseases, and digital health technologies. These innovative concepts often encompass novel platform technologies designed to tackle targets and diseases that were previously considered untreatable.

With a fund volume of EUR 350 million, the BIVF operates as an evergreen fund, continually reinvesting to fuel its mission. The partners of the BIVF gain from the fund’s deep expertise in drug discovery & development, translational science, and management, along with access to a network of experts within the Boehringer Ingelheim organization. Currently, the BIVF supports a diverse portfolio of over 40 companies, leveraging its extensive experience to drive progress in healthcare.

For additional information, please visit boehringer-ingelheim-venture.com.

Video: https://www.youtube.com/watch?v=TiujKeHvwzU
Photo: https://mma.prnewswire.com/media/2645475/MichalisPapadakis_CEO_Brainomix.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/brainomix-completes-14m-18m-series-c-round-to-advance-its-transformative-ai-imaging-technology-in-healthcare-302406209.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Converge Technology Solutions and H.I.G. Capital Agree to Amend Arrangement Agreement

Published

on

By

TORONTO and GATINEAU, QC, April 2, 2025 /PRNewswire/ — Converge Technology Solutions Corp. (“Converge” or the “Company”) (TSX: CTS) (FSE: 0ZB) (OTCQX: CTSDF) announced today that the Company has agreed to amend (the “Amendment”) the previously announced arrangement agreement dated February 6, 2025 (the “Arrangement Agreement”) with an affiliate of H.I.G. Capital (“H.I.G.”), whereby H.I.G has agreed to acquire all of the issued and outstanding common shares (the “Common Shares”) of the Company (the “Arrangement”). Under the terms of the Amendment, shareholders will receive C$6.00 per Common Share in cash (up from C$5.50 per Common Share), other than Common Shares held by certain shareholders who enter into rollover equity agreements. Defined terms used herein that are not otherwise defined have the meaning given to them in the Arrangement Agreement.

On March 7, 2025, Converge received an unsolicited, conditional, non-binding proposal (the “Unsolicited Proposal”) to acquire 100% of the Common Shares for cash consideration of C$6.00 per share from a credible third party (the “Third Party”). Consistent with its fiduciary duties, the board of directors of Converge (the “Board”), in consultation with its legal and financial advisors and a special committee of independent directors, confidentially considered and determined that the Unsolicited Proposal was a bona fide Acquisition Proposal that constitutes, or could reasonably be expected to constitute or lead to, a Superior Proposal.

On March 25, 2025, H.I.G. commenced a proceeding in the Ontario Superior Court of Justice (Commercial List) (the “Court”) claiming that Converge had, in engaging with the Third Party regarding the Unsolicited Proposal, breached certain provisions of the Arrangement Agreement and was therefore not permitted to accept or approve a Superior Proposal (if received) from the Third Party, or to enter into a definitive agreement with respect to any such Superior Proposal. By order of the Court, Converge was prohibited from making public disclosure of H.I.G.’s allegations. Converge denied such claims, rejected H.I.G.’s positions and undertook a vigorous defence of its position.

On March 31, 2025, Converge received an unsolicited, binding all-cash Acquisition Proposal from the Third Party at a price of C$6.00 per Common Share (the “Original Binding Proposal”). Following Converge’s receipt of the Original Binding Proposal, H.I.G. advised Converge that it was prepared to enter into the Amendment to increase the cash price under the Arrangement to C$6.00 per Common Share. On April 1, 2025, shortly before the Board determined to enter into the Amendment, the Third Party submitted an amended binding Acquisition Proposal in which the price per Common Share was increased by 1.7% to C$6.10 per share (the “Amended Binding Proposal”).

After carefully considering the Amended Binding Proposal and the Amendment, the Board unanimously (with an interested director abstaining), upon the recommendation of the special committee, and in consultation with its legal and financial advisors, determined that entering into the Amendment was in the best interests of the Company. In making their determination, the Board and the special committee considered, among other things, (i) that the Amendment offers shareholders of the Company a high degree of certainty of a completed transaction on a very short timeline at a price per Common Share that is significantly higher than the original C$5.50 price under the Arrangement and equal to the price offered under the Original Binding Proposal; and (ii) the benefits of such relative certainty to the business and the Company’s stakeholders, including its employees, customers and vendors. As part of entering into the Amendment, the Company and H.I.G. have also agreed to permanently discontinue the court proceedings described above and the Company has agreed to discontinue its discussions with the Third Party.

The Board unanimously (with an interested director abstaining) reiterates its recommendation that Shareholders vote FOR the Arrangement Resolution (as defined herein).

The Arrangement and Meeting Details

As originally planned, Converge will hold the special meeting of shareholders (the “Meeting”) to consider a special resolution to approve the Arrangement (the “Arrangement Resolution”) on April 10, 2025, at 11:00 a.m. (Toronto time) in a virtual-only meeting format. The Meeting will be held online at https://meetnow.global//MWUKHQ6, with the ability to participate electronically as explained further in the Circular. Only Shareholders of record as of the close of business on March 10, 2025 are entitled to receive notice of, attend, participate and vote at, the Meeting. The Arrangement is expected to be completed on or about April 17, 2025.

About Converge
Converge Technology Solutions Corp. is reimagining the way businesses think about IT—a vision driven by people, for people. Since 2017, we’ve focused on delivering outcomes-driven solutions that tackle human- centered challenges. As a services-led, software-enabled, IT & Cloud Solutions provider, we combine deep expertise, local connections, and global resources to deliver industry-leading solutions.

Through advanced analytics, artificial intelligence (AI), cloud platforms, cybersecurity, digital infrastructure, and workplace transformation, we empower businesses across industries to innovate, streamline operations, and achieve meaningful results. Our AIM (Advise, Implement, Manage) methodology ensures solutions are tailored to our customers’ specific needs, aligning with existing systems to drive success without complexity.

Discover IT reimagined with Converge—where innovation meets people. Learn more at convergetp.com.

Forward-Looking Information

This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation regarding Converge and its business. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected” “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”. “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Specifically, statements regarding the Amendment, the anticipated timing of the Meeting and the completion of the transactions contemplated thereby and other statements that are not statements of historical facts are considered forward-looking information. The anticipated dates indicated may change for a number of reasons, including the necessity to extend the time limits for satisfying the other conditions for the completion of the Arrangement. The forward-looking information are based on management’s opinions, estimates and assumptions. While these opinions, estimates and assumptions are considered by the Company to be appropriate and reasonable in the circumstances as of the date of this press release, they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking information.

The forward looking information are subject to significant risks including, without limitation: risks relating to the completion of a transaction with H.I.G., including receipt of all necessary regulatory, court, and shareholder approvals; and general economic conditions.

If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward- looking information, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information.

There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward- looking information contained in this press release represents the Company’s expectations as of the date specified herein, and are subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information or to publicly announce the results of any revisions to any of those statements, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements.

For further information contact: Converge Technology Solutions Corp., Email: investors@convergetp.com, Phone: 416-360-1495

View original content:https://www.prnewswire.co.uk/news-releases/converge-technology-solutions-and-hig-capital-agree-to-amend-arrangement-agreement-302417865.html

Continue Reading

Technology

SUEZ and Sonadezi Forge Strategic Partnership to Provide Integrated Environmental Solutions for Industrial Park in Vietnam

Published

on

By

HO CHI MINH CITY, Vietnam, April 2, 2025 /PRNewswire/ — SUEZ signed a joint venture agreement with Sonadezi, a state-owned company who has developed and currently manages 11 large-scale industrial parks in Vietnam, to provide integrated environmental solutions to the largest industrial park in South Vietnam. This strategic partnership marks SUEZ’s first industrial park project in Vietnam and its 22nd in Asia, reinforcing its commitment to supporting the region’s sustainable growth with circular, resilient industrial water and waste solutions.

François Fevrier, CEO Water and R&R of SUEZ Asia, said: “This partnership marks a major step for SUEZ into Vietnam’s industrial park sector. We have proven expertise and technical know-how in industrial parks across Asia, providing state-of-the-art environmental services to 22 parks in the region. We are pleased to join hands with Sonadezi to write the next chapter of our story in Vietnam. As the country continues to develop its industrial landscape, SUEZ is committed to supporting its vision for a more sustainable future, by providing innovative water and waste solutions.”

Since establishing its first industrial park in 1963, Vietnam has developed over 400 such parks. To address industrial water and wastewater challenges, such as improving wastewater quality, stabilising effluents from wastewater treatment plants and enhancing pipe network conditions, the government has introduced robust environmental and discharge policies, pushing for higher-quality development. As part of the country’s environmental transition, 40% to 50% localities in Vietnam aim to convert existing industrial parks into eco-industrial parks by 2030. Leveraging its expertise and extensive experience, SUEZ is well-positioned to play a role in advancing this transformation further.

Strategically situated just over an hour’s drive from Ho Chi Minh City, the Chau Duc Industrial Park, the largest of its kind in South Vietnam, is a vital hub for industrial activities. It serves as a gateway for international businesses looking to invest in Vietnam’s flourishing industrial sectors such as semiconductors, mechanics, and automotive accessories, and plays a crucial role in the national economic development.

The first phase of the collaboration between SUEZ and Sonadezi will involve the upgrade and Operations and Maintenance (O&M) of the existing wastewater treatment facilities and will provide comprehensive wastewater solutions to over 100 industrial clients within the Chau Duc Industrial Park. With the rapid development of the Park and the increasing standards of environmental goals of the country, the new joint venture will also study the opportunities to strengthen water and waste services within the Park through cutting-edge facilities and technologies.

With a 160-year track record in water and waste management, SUEZ has been providing integrated environmental solutions to 22 major industrial parks in Asia for over two decades. In Vietnam, SUEZ has been working closely with local partners since 1955, providing sustainable drinking water and wastewater services through more than 20 projects. The signing of this agreement is another milestone for SUEZ to provide industrial clients with reliable and cost-efficient solutions for their effluents and waste, supporting the country in achieving its sustainability goals.

About SUEZ:

Faced with growing environmental challenges, SUEZ has been delivering essential services that protect and improve our quality of life for more than 160 years. SUEZ provides its customers with innovative and resilient solutions for water and waste services. With 40,000 employees across 40 countries, the Group works with customers to create value over the full lifecycle of their assets and services, and to drive their low carbon transition. In 2023, SUEZ provided drinking water for 57 million people worldwide and sanitation services for more than 36 million people. The Group generated 7.7 TWh of energy from waste and wastewater. In 2023, SUEZ generated revenues of 8.9 billion euros. For more information: www.suez.com / X @suez / LinkedIn @SUEZ.

In Asia, SUEZ’s journey began some 70 years ago, first in Southeast Asia before expanding to China 50 years ago. With 6,500+ employees across Asia, SUEZ has built over 600 water and wastewater treatment plants. Together with our local partners, we also provide water and waste recycling and recovery services to 25+ million people and 22 industrial parks across the region. SUEZ is recognized as one of the most influential companies in China and a service benchmark for leading Asia’s environmental industry. Today, SUEZ works with municipal and industrial customers in more than 30 major cities and regions across China, manages China’s first PPP water contract in Macao, operates one of Asia’s largest hazardous waste incineration facilities in Shanghai, and has invested over RMB 6 billion in Chongqing.

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/suez-and-sonadezi-forge-strategic-partnership-to-provide-integrated-environmental-solutions-for-industrial-park-in-vietnam-302417870.html

SOURCE SUEZ Asia

Continue Reading

Technology

China Science Fiction Convention Concludes with Insightful “Sci-Fi+” Forums Exploring Future Frontiers

Published

on

By

BEIJING,  April 2, 2025 /PRNewswire/ — The China Science Fiction Convention 2025 (CSFC 2025) culminated with four high-profile thematic forums—”Sci-Fi + Talent,” “Sci-Fi + AI,” “Sci-Fi + Life Sciences,” and “Sci-Fi + Future Transportation”. The event took place on March 29-30 at Beijing’s Shijingshan District’s Shougang Park.

Themed “Science Dreams – Creating the Future,” CSFC 2025 featured five core segments: an opening ceremony, professional forums, competitions, industry promotion initiatives, and public engagement activities. The “Sci-Fi+” forums, a highlight of the event, were organized by the Beijing Association for Science and Technology and hosted by the China Center for International Communication Development (CCICD).

The “Sci-Fi+” forums brought together leading minds from academia, the private sector, and the arts, including senior researchers from the Chinese Academy of Sciences (CAS), officials from the Ministry of Science and Technology, and top management executives from China International Communications Group (CICG), Beijing Association for Science and Technology, Perfect World, iFlytek, Germany’s Steinbeis, as well as award-winning science fiction authors and international communication specialists. Key discussions spanned transformative trends:

“Sci-Fi + Talent”: Introduced the Interdisciplinary Sci-Fi Talent Development Program, proposing novel frameworks for interdisciplinary education.”Sci-Fi + AI”: Explored the intersection of AI and creative expression, highlighting collaborative potentials that redefine the relationship between humans and technology.”Sci-Fi + Life Sciences”: Featured a presentation by CAS Academician Chen Runsheng, discussing the inspirational role of science fiction in real scientific discovery.”Sci-Fi + Future Transportation”: Discussed next-gen mobility, from drone networks to hyperloops, driven by tech-sci-fi cross-pollination.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/china-science-fiction-convention-concludes-with-insightful-sci-fi-forums-exploring-future-frontiers-302417884.html

SOURCE China Center for International Communication Development (CCICD)

Continue Reading

Trending